Details for Patent: 9,611,283

Which drugs does patent 9,611,283 protect, and when does it expire?

Patent 9,611,283 protects ALUNBRIG and is included in one NDA.

Summary for Patent: 9,611,283

Title:	Methods for inhibiting cell proliferation in ALK-driven cancers
Abstract:	The invention features a method for treating patients who have an ALK-driven cancer, which is, or has become, refractory to one or more of crizotinib, CH5424802 and ASP3026, or which bears an ALK mutation identified herein, by administering a compound of formula (I) to the patient. The invention also features methods, kits, and compositions for characterizing ALK-driven cancers to determine whether they express an ALK mutant.
Inventor(s):	Zhang; Sen (Newton, MA), Shakespeare; William C. (Southborough, MA), Rivera; Victor M. (Arlington, MA)
Assignee:	Ariad Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/249,483
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,611,283

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ALUNBRIG	brigatinib	TABLET;ORAL	208772-001	Apr 28, 2017		RX	Yes	No						TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Takeda Pharms Usa	ALUNBRIG	brigatinib	TABLET;ORAL	208772-002	Apr 28, 2017		RX	Yes	No						TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Takeda Pharms Usa	ALUNBRIG	brigatinib	TABLET;ORAL	208772-003	Oct 2, 2017		RX	Yes	Yes						TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)